|

MAX - SHOCK Clinical Trial

RECRUITINGN/ASponsored by Ottawa Heart Institute Research Corporation
Actively Recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Started2025-03-31
Est. completion2027-09-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06556667

Summary

Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients age \> 18 years.
* Persistent atrial fibrillation.
* Scheduled for elective cardioversion at UOHI
* Patient is within the circle of care of UOHI Electrophysiology staff

Exclusion Criteria:

* Known left-atrial appendage thrombus.
* Contraindication to appropriate anticoagulation.
* Patient is included in another randomized clinical trial.
* Patient does not meet all of the above listed inclusion criteria.

Conditions3

Atrial FibrillationCardioversionHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.